Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles
Sarah Jessica Parker divides opinion with enormous hat on set of And Just Like That
Sarah Jessica Parker and her character Carrie Bradshaw seem to love pushing fashion boundaries, and2024-05-22Week in Politics: Luxon stands out, benefit action under scrutiny and grief over Efeso Collins
Christopher Luxon showcased his own party's agenda in the State of the Nation speech, according to c2024-05-22Wait times to see health specialists rise, childhood immunisations fall
Forty percent of patients (30,757) had waited more than four months for surgery or other treatments,2024-05-22Movement of pilot's seat a focus of probe into LATAM Boeing flight, report says
Photo: Marika Khabazi2024-05-22Iran helicopter crash: President Raisi, the supreme leader's protege, dies at 63
DUBAI, United Arab Emirates (AP) — Iranian President Ebrahim Raisi, a hard-line protege of the count2024-05-22Person seriously injured, another dead after Browns Bay assault
Photo: 123RF2024-05-22
atest comment